Human Genome Sciences Inc. (Nasdaq: HGSI) and GlaxoSmithKline (NYSE: GSK) announced that their lupus treatment Benlysta failed secondary goals in a late stage clinical trial. Shares of Human Genome tumbled $2.98 to $28.51 while GlaxoSmithKline stock edged up 13 cents to $39.51.
Drug Trial Fails For Human Genome And GlaxoSmithKline
April 20, 2010 at 13:22 PM EDT